News from synthetic biologics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 02, 2014, 08:04 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Announces First Patient Dosed in Phase 1a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Nov 24, 2014, 06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Safe-to-Proceed Under IND to Initiate Clinical Trials of SYN-004 for the Prevention C. difficile Infection

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Nov 14, 2014, 06:56 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Reports Third Quarter 2014 Financial Results and Operational Highlights

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Nov 06, 2014, 06:57 ET

Synthetic Biologics to Report Third Quarter 2014 Financial Results

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on...

Oct 22, 2014, 06:57 ET
Synthetic Biologics, Inc. Logo

Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel pathogen-specific therapies for serious infections and...

Oct 15, 2014, 06:58 ET
Synthetic Biologics, Inc. Logo.

Synthetic Biologics Appoints Prominent Gastrointestinal (GI) Key Opinion Leaders to Irritable Bowel Syndrome (IBS) Clinical Advisory Board

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologics and drugs targeting specific...

Oct 10, 2014, 08:55 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Raise $20.7 Million in Registered Direct Offering

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel biologics and drugs targeting specific pathogens that cause...

Sep 16, 2014, 10:35 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting...

Sep 12, 2014, 13:23 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting...

Sep 11, 2014, 06:58 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Host Phase II Trimesta™ for Multiple Sclerosis Conference Call

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific...

Sep 10, 2014, 12:04 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting...

Sep 08, 2014, 06:58 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting...

Sep 07, 2014, 08:58 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting...

Sep 03, 2014, 06:58 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that...

Sep 02, 2014, 07:33 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that...

Aug 28, 2014, 06:56 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause...

Aug 26, 2014, 06:58 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Announces Presentation of Poster for SYN-004 C. difficile Program at IDWeek 2014™

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting...

Aug 19, 2014, 06:56 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC

 Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting...

Aug 14, 2014, 06:58 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights

Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause...

Aug 13, 2014, 06:56 ET
Synthetic Biologics, Inc. Logo.  (PRNewsFoto/Synthetic Biologics, Inc.)

Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific...